Jean Pascal Machiels

Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial

Gwénaëlle Gravis, Karim Fizazi, Florence Joly et al. · The Lancet Oncology · 2013 · 740 citations

Medicine, Oncology, Urology +16

HER-2/neu is a tumor rejection target in tolerized HER-2/neu transgenic mice.

R. Todd Reilly, Morris B.C. Gottlieb, Anne M. Ercolini et al. · PubMed · 2000 · 216 citations · Full text

Medicine, Immunology, Oncology +16

Efficacy and safety of erdafitinib in patients with locally advanced or metastatic urothelial carcinoma: long-term follow-up of a phase 2 study

Arlene O. Siefker‐Radtke, Andrea Necchi, Se Hoon Park et al. · The Lancet Oncology · 2022 · 169 citations · Full text

Medicine, Oncology, Pharmacotherapy +11

Prognostic Factors for Survival in Noncastrate Metastatic Prostate Cancer: Validation of the Glass Model and Development of a Novel Simplified Prognostic Model

Gwénaëlle Gravis, Jean‐Marie Boher, Karim Fizazi et al. · European Urology · 2014 · 130 citations · Full text

Medicine, Oncology, Urology +14

An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Viktor Grünwald, Pierre I. Karakiewicz, Sevil Bavbek et al. · European Journal of Cancer · 2011 · 87 citations

Medicine, Oncology, Pharmacology +16